394 completed, 124 terminated, 121 recruiting, 106 unknown. 875 Phase 2, 224 Phase 1, 20 Phase 3.
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
Showing 20 of 875. Sign in to see all of them.
Lymphoma, Non-Hodgkin (317) · Lymphoma, Follicular (314) · Lymphoma (311) · Lymphoma, Mantle-Cell (283) · Leukemia, Lymphocytic, Chronic, B-Cell (236) · Burkitt Lymphoma (226) · Lymphoma, B-Cell, Marginal Zone (209) · Lymphoma, Large-Cell, Immunoblastic (193) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (185) · Hodgkin Disease (150) · Recurrence (133) · Waldenstrom Macroglobulinemia (106) · Leukemia (105) · Multiple Myeloma (102)
Hemic and Lymphatic Diseases (875) · Neoplasms by Histologic Type (866) · Immune System Diseases (863) · Immunoproliferative Disorders (860) · Lymphatic Diseases (860) · Lymphoproliferative Disorders (853) · Neoplasms (841) · Lymphoma, B-Cell (790) · Lymphoma (564) · Lymphoma, Non-Hodgkin (558) · Pathological Conditions, Signs and Symptoms (326) · Pathologic Processes (325) · Disease Attributes (319) · Hematologic Diseases (297) · Leukemia, Lymphoid (276)
Rituximab (275) · Cyclophosphamide (221) · Prednisone (108) · Etoposide (106) · Vincristine (106) · Doxorubicin (105) · Peripheral Blood Stem Cell Transplantation (72) · Lenalidomide (68) · Filgrastim (63) · fludarabine phosphate (57) · Cytarabine (54) · Gemcitabine (50) · Radiotherapy (50) · Mycophenolic Acid (47) · Melphalan (42)
National Cancer Institute (NCI) (50) · Fred Hutchinson Cancer Center (43) · Memorial Sloan Kettering Cancer Center (20) · Ruijin Hospital (16) · M.D. Anderson Cancer Center (15) · City of Hope Medical Center (14) · Case Comprehensive Cancer Center (13) · Mayo Clinic (13) · University of Nebraska (12) · Alliance for Clinical Trials in Oncology (11) · University of Washington (11) · Northwestern University (10) · Sun Yat-sen University (10) · Fondazione Italiana Linfomi - ETS (9) · Jonsson Comprehensive Cancer Center (9)
United States (526) · China (151) · France (75) · Italy (72) · United Kingdom (57) · Spain (55) · Germany (46) · South Korea (45) · Canada (40) · Australia (35) · Belgium (33) · Poland (30) · Czechia (22) · Netherlands (22) · Israel (20)
Ajay Gopal (8) · Brenda Sandmaier (6) · Craig Moskowitz, MD (6) · Julie M Vose, MD (5) · Asad Bashey, MD, PhD (4) · Christos E. Emmanouilides, MD (4) · Leo I. Gordon, MD (4) · Lode J. Swinnen, MD (4) · Sonali Smith (4)
PMID 34515338, PMID 32499241, PMID 39319495, PMID 40802906, PMID 26373676, PMID 27282998, PMID 17242396, PMID 21527516, PMID 23753028, PMID 23834234, PMID 24224624, PMID 24862638, PMID 30125215, PMID 30620669, PMID 31527168, PMID 34310745, PMID 34398557, PMID 38775302, PMID 10673703, PMID 12907446, PMID 1403051, PMID 14508361, PMID 14630682, PMID 14739217, PMID 14767498, PMID 15107815, PMID 15386331, PMID 15779863, PMID 16731764, PMID 16966261, PMID 17312330, PMID 17515574, PMID 17910637, PMID 17943599, PMID 18213528, PMID 18245545, PMID 18327587, PMID 18413640, PMID 18559976, PMID 18569634, PMID 18645482, PMID 18769450, PMID 18824292, PMID 19139736, PMID 19170225, PMID 19179301, PMID 19286996, PMID 19451441, PMID 1950172, PMID 19536896
P30CA015704 (17), 2023 (11), P30CA033572 (11), U10CA032102 (11), P30CA043703 (10), 2014 (9), 2015 (8), P30CA015083 (8), P30CA036727 (8), 2016 (7), N01CM62202 (6), P01CA018029 (6), P30CA022453 (6), P01CA078902 (5), P30CA006973 (5)